Drug intelligence / Profile preview

HC009 (Beijing Houcheng Pharmaceutical Technology)

Development stage: Unknown
Lead developer: Shanghai Hongcheng Pharmaceutical
Administration: Oral

Overview

HC009 is a Traditional Chinese Medicine (TCM) compound mixture developed by Beijing Houcheng Pharmaceutical Technology for the treatment of decreased ovarian reserve (DOR). It is specifically formulated to address the Kidney deficiency and liver stagnation syndrome (肾虚肝郁证) according to TCM diagnostic principles. The drug is currently being evaluated in Phase II clinical trials in China to assess its efficacy and safety in improving ovarian function and related symptoms in women with DOR. As a TCM mixture, it likely contains multiple botanical extracts intended to modulate the hypothalamic-pituitary-ovarian (HPO) axis and improve the ovarian microenvironment.

Other names: HC009合剂

Beyond the preview

Go deeper on HC009 (Beijing Houcheng Pharmaceutical Technology).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HC009 (Beijing Houcheng Pharmaceutical Technology).

Explore the full profile